313 millions shares outstanding...Let's talk about TLT shares counts.
As we speak almost all the heavy works in TLT bladder cancer trial has been done, and if there is a need for financing, it will be minimal.
Future PP for other cancer trials will be done at a much higher SP, and will also be financed with the help of a large Pharma JV money deal.
The above should limit future dillution to a bare minimum.
TLT has approximately 313 millions shares outstanding(warrants & options included).
Question?
Is 313 millions shares outstanding a big number?
Answer.
It depend on the value($) of TLT market opportunity.
A) In the June 28,2022 Market Presentation, TLT said " the market opportunity for the BCR-Unresponsive is approximately +2 to 5 billions$/year".
B) The next step for TLT, will be to go after the BCG-Shortage market, +5 to 10 billions$/year.
C) Next Lung(NSCLC) + XX billions$/year.
D) Next Brain(GBM) + XX billions$/year.
If you take into account only the BCG-Unresponsive market opportunity value($), then 313 millions is a puny little number of shares.
Question?
Is it possible for a pharma company that has a colossal 5.6 Billion shares outstanding to be a successful pharma company?
Answer yes.
Pfizer has a colossal 5.6 Billion shares outstanding, and is a successful pharma company.
In short...
I agree... TLT is not Pfizer, but with a puny little 313 millions shares outstanding, TLT has a lot's of room to spare on the shares counts.
And if there is a need for money, bring it on, with the huge market opportunities TLT has, the financing, and the shares counts will not stop TLT from being successful.
2023 is the year of TLT (not 2025).